Business Context and Reporting Period
X4 Pharmaceuticals, Inc. (XFOR) filed this Form 8-K on January 6, 2023, to report the entry into a material definitive agreement. The Company, along with its subsidiary X4 Therapeutics, Inc., entered into a Second Amended and Restated Loan and Security Agreement with Hercules Capital, Inc. and related entities.
Key Financial Metrics and Debt Structure
- Term Loan Amount: $32.5 million.
- Interest Rate: The greater of (i) 3.15% plus the Wall Street Journal prime rate or (ii) 10.15%. Interest is payable monthly.
- Default Interest: Increases by 4.0% upon an event of default.
- Maturity Date: April 1, 2026, with a potential extension to July 1, 2027 if certain conditions are met.
- Amortization: No scheduled payments prior to October 1, 2024; potentially extendable to January 1, 2026.
- Prepayment: Allowed at the Company's option (all or nothing) subject to a premium of up to 3.0%.
- Collateral: Substantially all personal property and assets, excluding intellectual property (though including rights to proceeds from IP).
- Liquidity Covenant: Must maintain cash and cash equivalents of at least $20.0 million (or $10.0 million after certain conditions are met).
Material Changes and Transaction Costs
The agreement amends and restates the First Amended and Restated Loan and Security Agreement dated June 27, 2019. The following payments were made or are due in connection with this transaction:
- Closing Payment: Approximately $1.4 million paid to Hercules on January 6, 2023, related to previously outstanding term loans.
- Deferred Payment 1: $763,750 due on the earliest of July 1, 2023, full prepayment, or default.
- Deferred Payment 2: $1.3 million due on the earliest of the maturity date, full prepayment, or default.
- Equity Participation: Hercules has the right to participate in future equity offerings for financing purposes up to $1.0 million in the aggregate.
Outlook, Risks, and Contingencies
The filing does not provide specific revenue guidance or management commentary on future operational performance. Key risks and contingencies identified include:
- Events of Default: Obligations are subject to acceleration upon payment default, insolvency, or a material adverse change in the Company's business or financial condition.
- Liquidity Requirements: The Company must strictly adhere to minimum liquidity covenants to avoid default.
- Future Financing: Future equity raises for financing purposes may be subject to Hercules' participation rights.
Investor Verification Checklist
- Verify the Company's current cash and cash equivalents balance against the $20.0 million minimum liquidity covenant.
- Review the full text of the Second Amended and Restated Loan and Security Agreement (to be filed as an exhibit to the 2022 Form 10-K) for detailed covenants and exceptions.
- Monitor the Company's ability to meet the $1.4 million closing payment and the subsequent deferred payments of $763,750 and $1.3 million.
- Assess the impact of the 10.15% minimum interest rate on future cash flow projections.
- Check for any upcoming equity offerings that might trigger Hercules' $1.0 million participation right.